194

DNA fragment generated by a specific restric- tion endonuclease and therefrom determining the presence of the allele. A second preferred method involves the serologic detection of the DQw3.2 allele. Within this method, immuno- complexes formed between two different MAb's and separate portions of a cell collection are detected and the presence or absence of the allele determined.

8607593

M E T H O D S A N D C O M P O S I T I O N S U S E F U L I N P R E V E N T I N G

E Q U I N E I N F L U E N Z A

Beverly DALE, Barbara CORDELL assigned to BIOTECHNOLOGY RESEARCH PART- NERS LIMITED

Recombinant vaccines for immunizing horses against equine influenza virus (EIV). The DNA sequences encoding the hemagglutinin (HA) and neuraminidase (NA) glycoproteins from the two strains of EIV currently infective in horses are used to construct vaccinia carried vaccines, to design synthetic peptides for primer and booster administration, and to permit recombinant syn- thesis of HA and/or NA protein based vaccines. These DNA sequences also provide probes use- ful for preparing similar vaccines from fresh isolates of new strains generated by genetic drift.

8607609

V E C T O R F O R T H E E X P R E S S I O N O F E T A - I N T E R F E R O N I N

M A M M A L C E L L S , M E T H O D F O R I T S I M P L E M E N T A T I O N ,

P R O D U C T O B T A I N E D A N D P H A R M A C E U T I C A L

C O M P O S I T I O N C O N T A I N I N G T H E E T A - I N T E R F E R O N

Th~a r(a se FAURE, Paul SONDERMEYER, Werner ALTENBURGER, Jean-Pierre LECOCQ, 67bis, route des Romains, F-67200 Koenighshiffen, France assigned to TRANS- GENES A;

The invention relates to a virus of the cow-pox, characterized in that it comprises all or part of a DNA sequence coding for IFN-eta. This virus may be used to infect mammal cells in order to obtain cells producing IFN-eta which may be used in therapeutical compositions.

PATENT ABSTRACTS

8607610

E X P R E S S I O N O F H U M A N IL-2 IN M A M M A L C E L L S BY M E A N S O F

A R E C O M B I N E D P O X V I R U S

Marie-Paule KIENY, Paul SONDERMEYER. Jean-Pierre LECOCQ, I 1, rue de Gascogne, F- 67000 Strasbourg, France assigned to TRANS- GENE S A:

The present invention relates to a poxvirus characterized in that it comprises all or part of DNA sequence coding for a human IL-2 protein.

8700043

M U L T I L A M E L L A R L I P O S O M E S H A V I N G I M P R O V E D T R A P P I N G

E F F I C I E N C I E S

Marcel B BALLY, Pieter R CULLIS, Michael J HOPE, Andrew S JANOFF, Lawrence D MAYER, 5516 Corvette Crescent, Vancouver, British Columbia V6T 1M 8, Canada assigned to THE LIPOSOME COMPANY 1NC:

A multitamellar vesicle dispersed in an aqueous phase comprising an aqueous medium, a lipid concentration of at least about 50 mg/ml and a trapping efficiency of at least about 30 percent. The vesicle can be prepared by dispersing the lipid in an aqueous phase to form a multilamellar vesicle, rapidly freezing the multilamellar vesicle to obtain a frozen lipid-aqueous medium mix- ture, and warming the mixture to obtain a frozen and thawed multilamellar vesicle dispersed in an aqueous phase.

8700054

P R O C E S S A N D C O M P O S I T I O N F O R T R E A T M E N T O F C A N C E R

A N D N O N - M A L I G N A N T T U M O R S

Gary R LANDUCCI, Toni N MARIANI as- signed to THE REGENTS OF THE UNIVER- SITY OF MINNESOTA

Processes and compositions for the immuno- therapeutic treatment of cancer and non- malignant tumors. More particularly, this invention relates to processes and compositions for enhancing the body's immune response by in- creasing the cytotoxic activity of cells which mediate antibody dependent cellular cyto- toxicity. Cells which are characterized by in- creased cytotoxic activity, as a result of the process of this invention, are useful in methods and compositions for the treatment of various types of cancer and non-malignant tumors.